Roles of the Bcl-2/Bax ratio, caspase-8 and 9 in resistance of breast cancer cells to paclitaxel

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 20, 2014, Pages 8617-8622

  Sharifi, Simin ^a,b   Barar, Jaleh ^a,c   Hejazi, Mohammad Saeid ^a,b   Samadi, Nasser ^a,b,c  

^a Faculty of Pharmacy   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Bcl 2 Bax; Breast cancer cells; Caspases; Chemoresistance; MCF 7; Paclitaxel

Indexed keywords

ANTINEOPLASTIC AGENT; BAX PROTEIN, HUMAN; CASPASE 8; CASPASE 9; PACLITAXEL; PROTEIN BAX; PROTEIN BCL 2; TUMOR MARKER;

ANALYSIS OF VARIANCE; BREAST NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENETICS; HUMAN; MCF 7 CELL LINE; METABOLISM; PATHOLOGY; SENSITIVITY AND SPECIFICITY; TUMOR CELL LINE;

ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BCL-2-ASSOCIATED X PROTEIN; BREAST NEOPLASMS; CASPASE 8; CASPASE 9; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MCF-7 CELLS; PACLITAXEL; PROTO-ONCOGENE PROTEINS C-BCL-2; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84911164430     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.20.8617     Document Type: Article

References (59)

1. Bargou RC, Wagener C, Bommert K, et al (1996). Overexpression of the death-promoting gene Bax-alpha which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in SCID mice. J Clin Invest, 97, 2651-9.
2. Carrick S, Parker S, Thornton CE, et al (2009). Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev, 2, 3372.
3. Childs AC, Phaneuf SL, Dirks AJ, et al (2002). Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2:Bax ratio. Cancer Res, 62, 4592-8.
4. Chinnaiyan AM (1999). The apoptosome: heart and soul of the cell death machine. Neoplasia, 1, 5-15.
5. Chipuk JE, Bouchier-Hayes L and Green DR (2006). Mitochondrial outer membrane permeabilization during apoptosis: the innocent bystander scenario. Cell Death Differ, 13, 1396-402.
6. Chipuk JE, Moldoveanu T, Llambi F, et al (2010). The Bcl-2 family reunion. Mol Cell, 37, 299-310.
7. Coley HM (2004). Development of drug-resistant models. Methods Mol Med, 88, 267-73.
8. Crawford A and Nahta R (2011). Targeting Bcl-2 in herceptinresistant breast cancer cell lines. Curr Pharmacogenomics Person Med, 9, 184-90.
9. Crotzer DR, Sun CC, Coleman RL, et al (2007). Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol Oncol, 105, 404-8.
10. Cryns V and Yuan J (1998). Proteases to die for. Genes Dev, 12, 1551-70.
11. Danial NN and Korsmeyer SJ (2004). Cell death: critical control points. Cell, 116, 205-19.
12. Darakhshan S, Bidmeshkipour A, Khazaei M, et al (2013). Synergistic effects of tamoxifen and tranilast on VEGF and MMP-9 regulation in cultured human breast cancer cells. Asian Pac J Cancer Prev, 14, 6869-74.
13. Degterev A, Boyce M and Yuan J (2003). A decade of caspases. Oncogene, 22, 8543-67.
14. Ferreira KS, Kreutz C, Macnelly S, et al (2012). Caspase-3 feeds back on caspase-8, Bid and XIAP in type I Fas signaling in primary mouse hepatocytes. Apoptosis, 17, 503-15.
15. Fulda S, Debatin KM (2006). Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene, 25, 4798-811.
16. Gabizon A, Papahadjopoulos D (1988). Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci USA, 85, 6949-53.
17. Gabizon A, Price DC, Huberty J, et al (1990). Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: biodistribution and imaging studies. Cancer Res, 50, 6371-8.
18. Gabizon AA (1992). Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in longcirculating liposomes. Cancer Res, 52, 891-6.
19. Garcia M, Jemal A, Ward E, et al (2007). Global cancer facts & figures 2007. Atlanta, GA: American cancer society, 1.
20. Gee JM, Robertson JF, Ellis IO, et al (1994). Immunocytochemical localization of Bcl-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer, 59, 619-28.
21. Ghanbari P, Mohseni M, Tabasinezhad M, et al (2014). Inhibition of survivin restores the sensitivity of breast cancer cells to docetaxel and vinblastine. Appl Biochem Biotechnol, 174, 667-81.
22. Ghafouri-Fard S, Abdollahi DZ, Omrani M, et al (2012). shRNA mediated RHOXF1 silencing influences expression of BCL2 but not CASP8 in MCF-7 and MDA-MB-231 cell lines. Asian Pac J Cancer Prev, 13, 5865-9.
23. Hamedeyazdan S, Fathiazad F, Sharifi S, et al (2012). Antiproliferative activity of Marrubium persicum extract in the MCF-7 human breast cancer cell line. Asian Pac J Cancer Prev, 13, 5843-8.
24. Hembruff SL, Laberge ML, Villeneuve DJ, et al (2008). Role of drug transporters and drug accumulation in the temporal acquisition of drug resistance. BMC Cancer, 8, 318.
25. Iseri OD, Kars MD, Arpaci F, et al (2010). Gene expression analysis of drug-resistant MCF-7 cells: implications for relation to extracellular matrix proteins. Cancer Chemother Pharmacol, 65, 447-55.
26. Janicke RU, Sprengart ML, Wati MR, et al (1998). Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem, 273, 9357-60.
27. Kelly PN and Strasser A (2011). The role of Bcl-2 and its prosurvival relatives in tumourigenesis and cancer therapy. Cell Death Differ, 18, 1414-24.
28. Leung LK and Wang TT (1999). Differential effects of chemotherapeutic agents on the Bcl-2/Bax apoptosis pathway in human breast cancer cell line MCF-7. Breast Cancer Res Treat, 55, 73-83.
29. Lindsay J, Esposti MD and Gilmore AP (2011). Bcl-2 proteins and mitochondria--specificity in membrane targeting for death. Biochim Biophys Acta, 1813, 532-9.
30. McDermott M, Eustace AJ, Busschots S, et al (2014). In vitro development of chemotherapy and targeted therapy drugresistant cancer cell lines: a practical guide with case studies. Front Oncol, 4, 40.
31. Moulder S, Hortobagyi GN (2008). Advances in the treatment of breast cancer. Clin Pharmacol Ther, 83, 26-36.
32. Ola MS, Nawaz M and Ahsan H (2011). Role of Bcl-2 family proteins and caspases in the regulation of apoptosis. Mol Cell Biochem, 351, 41-58.
33. Olsson M and Zhivotovsky B (2011). Caspases and cancer. Cell Death Differ, 18, 1441-9.
34. Oltvai ZN, Milliman CL and Korsmeyer SJ (1993). Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell, 74, 609-19.
35. Ouyang L, Shi Z, Zhao S, et al (2012). Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. Cell Prolif, 45, 487-98.
36. Parkin DM, Bray F, Ferlay J, et al (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108.
37. Piche A, Grim J, Rancourt C, et al (1998). Modulation of Bcl-2 protein levels by an intracellular anti-Bcl-2 single-chain antibody increases drug-induced cytotoxicity in the breast cancer cell line MCF-7. Cancer Res, 58, 2134-40.
38. Pommier Y, Sordet O, Antony S, et al (2004). Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene, 23, 2934-49.
39. Rastogi RP, Sinha RP (2009). Apoptosis: molecular mechanisms and pathogenicity. EXCLI J, 8, 155-81.
40. Reed JC (1998). Bcl-2 family proteins. Oncogene, 17, 3225-36.
41. Ring AE and Ellis PA (2005). Taxanes in the treatment of early breast cancer. Cancer Treat Rev, 31, 618-27.
42. Sabzichi M, Hamishehkar H, Ramezani F, et al. (2014). Luteolinloaded phytosomes sensitize human breast carcinoma MDAMB 231 cells to doxorubicin by suppressing Nrf2 mediated signalling. Asian Pac J Cancer Prev, 15, 5311-6.
43. Saloustros E, Mavroudis D, Georgoulias V (2008). Paclitaxel and docetaxel in the treatment of breast cancer. Expert Opin Pharmacother, 9, 2603-16.
44. Scaffidi C, Fulda S, Srinivasan A, et al (1998). Two CD95 (APO-1/Fas) signaling pathways. EMBO J, 17, 1675-87.
45. Schrohl AS, Meijer-van Gelder ME, Holten-Andersen MN, et al (2006). Primary tumor levels of tissue inhibitor of metalloproteinases-1 are predictive of resistance to chemotherapy in patients with metastatic breast cancer. Clin Cancer Res, 12, 7054-8.
46. Seifi-Alan M, Shamsi R, Ghafouri-Fard S, et al (2013). Expression analysis of two cancer-testis genes, FBXO39 and TDRD4, in breast cancer tissues and cell lines. Asian Pac J Cancer Prev, 14, 6625-9.
47. Seve P, Isaac S, Tredan O, et al (2005). Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res, 11, 5481-6.
48. Shajahan AN, Dobbin ZC, Hickman FE, et al (2012). Tyrosinephosphorylated caveolin-1 (Tyr-14) increases sensitivity to paclitaxel by inhibiting BCL2 and BCLxL proteins via c-Jun N-terminal kinase (JNK). J Biol Chem, 287, 17682-92.
49. Simstein R, Burow M, Parker A, et al (2003). Apoptosis, chemoresistance, and breast cancer: insights from the MCF-7 cell model system. Exp Biol Med (Maywood), 228, 995-1003.
50. Stoetzer OJ, Nussler V, Darsow M, et al (1996). Association of Bcl-2, Bax, bcl-xL and interleukin-1 beta-converting enzyme expression with initial response to chemotherapy in acute myeloid leukemia. Leukemia, 10, 18-22.
51. Strasser A, Harris AW, Huang DC, et al (1995). Bcl-2 and Fas/ APO-1 regulate distinct pathways to lymphocyte apoptosis. EMBO J, 14, 6136-47.
52. Tabasinezhad M, Samadi N, Ghanbari P, et al (2013). Sphingosin 1-phosphate contributes in tumor progression. J Cancer Res Ther, 9, 556-63.
53. Tang D, Lahti JM, Kidd VJ (2000). Caspase-8 activation and bid cleavage contribute to MCF7 cellular execution in a caspase-3-dependent manner during staurosporine-mediated apoptosis. J Biol Chem, 275, 9303-7.
54. Thornberry NA, Lazebnik Y (1998). Caspases: enemies within. Science, 281, 1312-6.
55. Wang H, Vo T, Hajar A, et al (2014). Multiple mechanisms underlying acquired resistance to taxanes in selected docetaxel-resistant MCF-7 breast cancer cells. BMC Cancer, 14, 37.
56. Ward S, Simpson E, Davis S, et al (2007). Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation. Health Technol Assess, 11, 1-144.
57. Wild PJ, Reichle A, Andreesen R, et al (2004). Microsatellite instability predicts poor short-term survival in patients with advanced breast cancer after high-dose chemotherapy and autologous stem-cell transplantation. Clin Cancer Res, 10, 556-64.
58. Yang E and Korsmeyer SJ (1996). Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood, 88, 386-401.
59. Zuo KQ, Zhang XP, Zou J, et al (2010). Establishment of a paclitaxel resistant human breast cancer cell strain (MCF-7/ Taxol) and intracellular paclitaxel binding protein analysis. J Int Med Res, 38, 1428-35.